Erythropoietin (Epo) is a normal constituent of human milk, but the origin
and fate of this cytokine in milk are not known. Regarding its origin, we h
ypothesized that cells of the mammary gland secrete Epo into milk actively
and, therefore, that concentrations in milk do not correlate with concentra
tions in serum. Regarding its fate, we hypothesized that Epo concentrations
in milk change with time postpartum and that Epo in milk is protected from
digestion in the neonatal gastrointestinal tract. To address these issues,
we measured Epo concentrations in 103 milk samples (ELISA), 55 of which we
re paired with serum. Mammary duct epithelial cells were evaluated as a sou
rce of Epo by breast tissue immunohistochemistry and by cell culture. Circu
lating and milk Epo were compared by Western analysis to detect size differ
ences, possibly reflecting differences in processing. Epo stability in simu
lated conditions of digestion was evaluated. We observed that milk Epo conc
entrations increase as a function of duration of breast-feeding and have a
negative correlation with serum Epo or milk protein concentration. Mammary
duct epithelial cells from breast biopsies of lactating women had marked im
munoreactivity to Epo, but such activity was minimal to absent in nonlactat
ing breast tissue. Further evidence that mammary duct epithelia produce Epo
was obtained by observing Epo mRNA and protein expression in cultured huma
n mammary epithelial cells. The molecular size of Epo in milk and serum is
identical. Recombinant Epo added to human milk or commercial infant formula
s was relatively stable in conditions that simulate gastric and small intes
tinal conditions of newborn infants; however, recombinant Epo added to D5W
was not protected from digestion. We conclude that Epo concentrations in mi
lk increase as a function of the duration of breast feeding, that Epo is ac
tively secreted into human milk by mammary duct epithelia, and that the Epo
within milk is largely protected from digestion.